urmjУральский медицинский журналUral Medical Journal2949-4389Ural State Medical University10.52420/2071-5943-2022-21-6-58-68urmj-1124Research ArticleКАРДИОЛОГИЯCARDIOLOGYВлияние регулярного приема статинов на развитие сердечно-сосудистых событий в острый период COVID-19 и в течение трех месяцев после выписки из инфекционного госпиталя. Часть 2. Анализ пациентов, выписанных из инфекционного госпиталяEffect of regular statin intake on the development of cardiovascular events in the acute period of COVID-19 and within three months after discharge from the infectious diseases hospital. Part II. Analysis of patients discharged from the infectious diseases hospitalhttps://orcid.org/0000-0001-5063-5571КлячинаЕ. С.KlyachinaE. S.

Екатерина Сергеевна Клячина – ассистент кафедры

Екатеринбург

Ekaterina S. Klyachina – Department assistant

Ekaterinburg

katrina.s.sharm@gmail.comhttps://orcid.org/0000-0002-0705-6651СмоленскаяО. Г.SmolenskayaO. G.

Ольга Георгиевна Смоленская – доктор медицинских наук, профессор

Екатеринбург

Olga G. Smolenskaya – Doctor of Science (Medicine), Professor

Ekaterinburg

o.smolenskaya@mail.ruМакарочкинА. Г.MakarochkinA. G.

Андрей Геннадьевич Макарочкин – кандидат медицинских наук

Екатеринбург

Andrej G. Makarochkin – Ph.D. in medicine

Ekaterinburg

makar-e343@mail.ruhttps://orcid.org/0000-0001-5219-9216ВеденскаяС. С.VedenskayaS. S.

Светлана Сергеевна Веденская – кандидат медицинских наук

Екатеринбург

Svetlana S. Vedenskaya – Ph.D. in medicine

Ekaterinburg

svedenskaya@gmail.coУральский государственный медицинский университетРоссияUral State Medical UniversityRussian Federation2022071220222165868Copyright © Клячина Е.С., Смоленская О.Г., Макарочкин А.Г., Веденская С.С., 20222022Клячина Е.С., Смоленская О.Г., Макарочкин А.Г., Веденская С.С.Klyachina E.S., Smolenskaya O.G., Makarochkin A.G., Vedenskaya S.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.umjusmu.ru/jour/article/view/1124Введение

Введение. В настоящее время имеются данные о благоприятном влиянии статинов среди пациентов в остром периоде COVID-19. Гораздо меньше известно о влиянии приема статинов на состояние здоровья у пациентов в ближайшем периоде после выздоровления от COVID-19, особенно у больных с сопутствующей кардиологической патологией .

Цель исследования

Цель исследования. Оценить взаимосвязь регулярного приема статинов с развитием сердечно-сосудистых событий у выписанных пациентов с сердечно-сосудистой патологией в острый период COVID-19 и в течение трех месяцев после выписки из инфекционного госпиталя.

Материалы и методы

Материалы и методы. Проведено ретроспективное когортное обсервационное исследование пациентов, переболевших COVID-19, имеющих в анамнезе (до COVID-19) сердечно-сосудистые патологии, при которых показан регулярный прием гиполипидемических препаратов. С пациентами, выписанными из инфекционного госпиталя, через три месяца были проведены телефонные беседы и очные визиты.

Результаты

Результаты. В течение первых трех месяцев после выписки из инфекционного госпиталя у пациентов, не принимающих статины, зарегистрировано 9 (21,95 %) новых сердечно-сосудистых событий . В группе пациентов, принимавших статины, зарегистрировано 1 (3,03 %) сердечно-сосудистое событие. Шансы развития сердечно-сосудистых событий у пациентов в группе пациентов, не принимающих статины, были в 9 раз выше, чем при регулярном приеме (ОШ 0,11; 95 % ДИ: 0,01–0,92), р = 0,036.

Обсуждение

Обсуждение. Положительный эффект от приема статинов, наблюдаемый у выписанных пациентов после COVID-19, может быть обусловлен их дополнительными плейотропными эффектами.

Выводы

Выводы. Использование статинов у пациентов с сердечно-сосудистой патологией было связано со значительным снижением сердечно-сосудистых событий в течение трех месяцев после выписки из инфекционного госпиталя.

Introduction. Currently, there is evidence of a beneficial effect of statins among patients in the acute period of COVID-19. Much less is known about the effect of taking statins on the health of patients in the immediate period after recovery from COVID-19, especially in patients with concomitant cardiological pathology.

The aim of the study was to evaluate the relationship of regular statin intake with the development of cardiovascular events in discharged patients with cardiovascular pathology during the acute period of COVID-19 and within 3 months after discharge from the infectious diseases hospital.

Materials and methods A retrospective, cohort, observational study of patients who have had COVID-19 and have a history (before COVID-19) of cardiovascular pathologies, in which regular intake of hypolipidemic drugs is indicated, was conducted. Telephone and face-to-face visits were conducted with patients discharged from the infectious diseases hospital after 3 months.

Results During the first three months after discharge from the infectious diseases hospital, 9 (21,95 %) new cardiovascular events were registered in patients not taking statins. In the subgroup of patients taking statins, 1 (3,03 %) cardiovascular event was registered. The chances of developing cardiovascular events in patients in the subgroup of patients not taking statins were 9 times higher than with regular administration (OR 0,11; 95% CI: 0,01–0,92), p = 0,036.

Discussion The positive effect of taking statins observed in discharged patients after COVID-19 may be due to their additional pleiotropic effects.

Conclusion The use of statins in patients with cardiovascular pathology was associated with a significant decrease in cardiovascular events within 3 months after discharge from the infectious diseases hospital.

COVID-19осложнения COVID-19статиныCOVID-19complications COVID-19statinsReferencesBaigent C., Blackwell L., Emberson J. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. https://doi.org/10.1016/S0140-6736(10)61350-5.Baigent C., Blackwell L., Emberson J. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. https://doi.org/10.1016/S0140-6736(10)61350-5.Montori V.M., Devereaux P.J., Adhikari N.K. Randomized trials stopped early for benefit: a systematic review. JAMA. 2005;294(17):2203–2209. https://doi.org/10.1001/jama.294.17.2203.Montori V.M., Devereaux P.J., Adhikari N.K. Randomized trials stopped early for benefit: a systematic review. JAMA. 2005;294(17):2203–2209. https://doi.org/10.1001/jama.294.17.2203.Subir R., Jagat J.M., Kalyan K.G. Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19). Diabetes Metab Syndr. 2020;14(5):1225–1229. https://doi.org/10.1016/j.dsx.2020.07.011.Subir R., Jagat J.M., Kalyan K.G. Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19). Diabetes Metab Syndr. 2020;14(5):1225–1229. https://doi.org/10.1016/j.dsx.2020.07.011.Adam O., Ulrich L., James L.K. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120(1):229– 243. https://doi.org/10.1161/CIRCRESAHA.116.308537.Adam O., Ulrich L., James L.K. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120(1):229– 243. https://doi.org/10.1161/CIRCRESAHA.116.308537.Reiner Z., Hatamipour M., Banach M. et al. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci. 2020;16(3):490–496. https://doi.org/10.5114/aoms.2020.94655.Reiner Z., Hatamipour M., Banach M. et al. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci. 2020;16(3):490–496. https://doi.org/10.5114/aoms.2020.94655.Zhang X.J., Qin J.J., Cheng X. et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 2020;32(2):176–187. https://doi.org/10.1016/j.cmet.2020.06.015.Zhang X.J., Qin J.J., Cheng X. et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 2020;32(2):176–187. https://doi.org/10.1016/j.cmet.2020.06.015.Клячина Е.С., Смоленская О.Г., Макарочкин А.Г., Веденская С.С. Влияние регулярного приёма статинов на развитие сердечно-сосудистых событий в острый период COVID-19 и в течение трёх месяцев после выписки из инфекционного госпиталя. Часть 1. Анализ пациентов с летальным исходом в период госпитализации. Уральский медицинский журнал. 2022;21(5):58–66. http://doi.org/10.52420/2071-5943-2022-21-5-58-66.Клячина Е.С., Смоленская О.Г., Макарочкин А.Г., Веденская С.С. Влияние регулярного приёма статинов на развитие сердечно-сосудистых событий в острый период COVID-19 и в течение трёх месяцев после выписки из инфекционного госпиталя. Часть 1. Анализ пациентов с летальным исходом в период госпитализации. Уральский медицинский журнал. 2022;21(5):58–66. http://doi.org/10.52420/2071-5943-2022-21-5-58-66.Nguyen L.S., Dolladille C., Drici M.D. et al. Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database. Circulation. 2020;142(3):303–305. http://doi.org/10.1161/CIRCULATIONAHA.120.048238.Nguyen L.S., Dolladille C., Drici M.D. et al. Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database. Circulation. 2020;142(3):303–305. http://doi.org/10.1161/CIRCULATIONAHA.120.048238.Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711–1718. http://doi.org/10.1001/jama.285.13.1711.Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711–1718. http://doi.org/10.1001/jama.285.13.1711.Ridker P.M., Cannon C.P., Morrow D. et. al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20–28. http://doi.org/10.1056/NEJMoa042378.Ridker P.M., Cannon C.P., Morrow D. et. al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20–28. http://doi.org/10.1056/NEJMoa042378.Murad O., Palmer J., Sowers J, McFarlane S.I. Statins and CVD prevention in the diabetic population: implications of the CARDS trial. Curr Diab Rep. 2005;5(3):191–193. http://doi.org/10.1007/s11892-005-0008-1.Murad O., Palmer J., Sowers J, McFarlane S.I. Statins and CVD prevention in the diabetic population: implications of the CARDS trial. Curr Diab Rep. 2005;5(3):191–193. http://doi.org/10.1007/s11892-005-0008-1.Sever P.S., Poulter N.R., Dahlöf B., Wedel H. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Am J Cardiol. 2005;96(5A):39F–44F. http://doi.org/10.1016/j.amjcard.2005.06.025.Sever P.S., Poulter N.R., Dahlöf B., Wedel H. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Am J Cardiol. 2005;96(5A):39F–44F. http://doi.org/10.1016/j.amjcard.2005.06.025.LaRosa J.C., Grundy S.M., Waters D.D. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–1435. http://doi.org/10.1056/NEJMoa050461.LaRosa J.C., Grundy S.M., Waters D.D. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–1435. http://doi.org/10.1056/NEJMoa050461.Pedersen T.R., Faergeman O., Kastelein J.J. et. al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437– 2445. http://doi.org/10.1001/jama.294.19.2437.Pedersen T.R., Faergeman O., Kastelein J.J. et. al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437– 2445. http://doi.org/10.1001/jama.294.19.2437.Nissen S.E., Tuzcu E.M., Schoenhagen P. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071–1080. http://doi.org/10.1001/jama.291.9.1071.Nissen S.E., Tuzcu E.M., Schoenhagen P. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071–1080. http://doi.org/10.1001/jama.291.9.1071.Yuan S. Statins may decrease the fatality rate of middle east respiratory syndrome infection. mBio. 2015;6(4):e01120. http://doi.org/10.1128/mBio.01120-15.Yuan S. Statins may decrease the fatality rate of middle east respiratory syndrome infection. mBio. 2015;6(4):e01120. http://doi.org/10.1128/mBio.01120-15.Koushki K., Shahbaz S.K., Mashayekhi K. Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways. Clin Rev Allergy Immunol. 2020;6(10):175-199. http://doi.org/10.1007/s12016-020-08791-9.Koushki K., Shahbaz S.K., Mashayekhi K. Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways. Clin Rev Allergy Immunol. 2020;6(10):175-199. http://doi.org/10.1007/s12016-020-08791-9.Varga Z., Flammer A.J., Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–1418. http://doi.org/10.1016/S0140-6736(20)30937-5.Varga Z., Flammer A.J., Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–1418. http://doi.org/10.1016/S0140-6736(20)30937-5.Nägele M.P., Haubner B., Tanner F.C. et al. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis. 2020;314:58–62. http://doi.org/10.1016/j.atherosclerosis.2020.10.014.Nägele M.P., Haubner B., Tanner F.C. et al. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis. 2020;314:58–62. http://doi.org/10.1016/j.atherosclerosis.2020.10.014.Reriani M.K., Dunlay S.M., Gupta B. et al. Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials. Eur J Cardiovasc Prev Rehabil. 2011;18(5):704–716. http://doi.org/10.1177/1741826711398430.Reriani M.K., Dunlay S.M., Gupta B. et al. Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials. Eur J Cardiovasc Prev Rehabil. 2011;18(5):704–716. http://doi.org/10.1177/1741826711398430.Margaritis M., Channon K.M., Antoniades C. Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering. Antioxid Redox Signal. 2014;20(8):1198–1215. http://doi.org/10.1089/ars.2013.5430.Margaritis M., Channon K.M., Antoniades C. Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering. Antioxid Redox Signal. 2014;20(8):1198–1215. http://doi.org/10.1089/ars.2013.5430.Penny W.F., Ben-Yehuda O., Kuroe K. et al. Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein. J Am Coll Cardiol. 2001;37(3):766–774. http://doi.org/10.1016/s0735-1097(00)01180-3.Penny W.F., Ben-Yehuda O., Kuroe K. et al. Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein. J Am Coll Cardiol. 2001;37(3):766–774. http://doi.org/10.1016/s0735-1097(00)01180-3.Rodrigues-Diez R.R., Tejera-Muñoz A., Marquez-Exposito L. Statins: could an old friend help in the fight against COVID-19? Br J Pharmacol. 2020;177(21):4873–4886. http://doi.org/10.1111/bph.15166.Rodrigues-Diez R.R., Tejera-Muñoz A., Marquez-Exposito L. Statins: could an old friend help in the fight against COVID-19? Br J Pharmacol. 2020;177(21):4873–4886. http://doi.org/10.1111/bph.15166.Fernández-Oliva A., Ortega-González P., Risco C. Targeting host lipid flows: Exploring new antiviral and antibiotic strategies. Cell Microbiol. 2019;21(3):e12996. http://doi.org/10.1111/cmi.12996.Fernández-Oliva A., Ortega-González P., Risco C. Targeting host lipid flows: Exploring new antiviral and antibiotic strategies. Cell Microbiol. 2019;21(3):e12996. http://doi.org/10.1111/cmi.12996.Sasidhar M.V., Chevooru S.K., Eickelberg O. Downregulation of monocytic differentiation via modulation of CD147 by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. PLoS One. 2017;12(12):e0189701. http://doi.org/10.1371/journal.pone.0189701.Sasidhar M.V., Chevooru S.K., Eickelberg O. Downregulation of monocytic differentiation via modulation of CD147 by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. PLoS One. 2017;12(12):e0189701. http://doi.org/10.1371/journal.pone.0189701.Daniels L.B., Sitapati A.M., Zhang J. et al. Relation of statin use prior to admission to severity and recovery among COVID-19 inpatients. Am J Cardiol. 2020;136:149–155. http://doi.org/10.1016/j.amjcard.2020.09.012.Daniels L.B., Sitapati A.M., Zhang J. et al. Relation of statin use prior to admission to severity and recovery among COVID-19 inpatients. Am J Cardiol. 2020;136:149–155. http://doi.org/10.1016/j.amjcard.2020.09.012.Rossi R., Talarico M., Coppi F., Boriani G. Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action. Intern Emerg Med. 2020;15(8):1573–1576. http://doi.org/10.1007/s11739-020-02504-y.Rossi R., Talarico M., Coppi F., Boriani G. Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action. Intern Emerg Med. 2020;15(8):1573–1576. http://doi.org/10.1007/s11739-020-02504-y.

The authors declare that there are no conflicts of interest present.